Christopher M. Starr
CIK: 0001235470
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Monopar Therapeutics
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Oct 1, 2026MNPR
Monopar Therapeutics
Sale(S)Direct799 shares at avg. $79.67$64K - Oct 1, 2026MNPR
Monopar Therapeutics
Exercise(M)Direct8.4K shares at avg. $0.01$42 - Oct 1, 2026MNPR
Monopar Therapeutics
Sale(S)Direct4.6K shares at avg. $78.09$362K - Oct 1, 2026MNPR
Monopar Therapeutics
Sale(S)Direct3K shares at avg. $78.82$234K - Dec 2, 2025MNPR
Monopar Therapeutics
Award(A)DirectStock Options
2.9K shares- - Jul 14, 2025MNPR
Monopar Therapeutics
In-the-Money(X)Direct16.8K shares at avg. $0.01$84 - Jul 14, 2025MNPR
Monopar Therapeutics
Sale(S)Direct16.8K shares at avg. $40.00$672K - Mar 4, 2025MNPR
Monopar Therapeutics
Award(A)DirectStock Options
11.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 | MNPR Monopar Therapeutics | Sale(S) | 799 | $79.67 | $63,656 | Direct |
| Oct 1, 2026 | MNPR Monopar Therapeutics | Exercise(M) | 8,400 | $0.01 | $42 | Direct |
| Oct 1, 2026 | MNPR Monopar Therapeutics | Sale(S) | 4,631 | $78.09 | $361,635 | Direct |
| Oct 1, 2026 | MNPR Monopar Therapeutics | Sale(S) | 2,970 | $78.82 | $234,095 | Direct |
| Dec 2, 2025 | MNPR Monopar Therapeutics | Award(A) Stock Options | 2,924 | - | - | Direct |
| Jul 14, 2025 | MNPR Monopar Therapeutics | In-the-Money(X) | 16,800 | $0.01 | $84 | Direct |
| Jul 14, 2025 | MNPR Monopar Therapeutics | Sale(S) | 16,800 | $40.00 | $672,020 | Direct |
| Mar 4, 2025 | MNPR Monopar Therapeutics | Award(A) Stock Options | 11,365 | - | - | Direct |
1-8 of 8 transactions
About STARR CHRISTOPHER M
STARR CHRISTOPHER M (SEC CIK 0001235470) files insider reports with the SEC as Director of Monopar Therapeutics (MNPR).
Signal8 holds 4 ownership filings by STARR CHRISTOPHER M, all Form 4s, filed between Mar 7, 2025 and Oct 5, 2026. Those filings report 8 transactions, from Mar 4, 2025 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on STARR CHRISTOPHER M's filings is in WILMETTE, IL.
Recent filings by STARR CHRISTOPHER M
- Oct 1, 2026: Open-market sale of MNPR shares (Form 4, code S).
- Oct 1, 2026: Option exercise of MNPR shares (Form 4, code M).
- Oct 1, 2026: Open-market sales of MNPR shares (2 lines, Form 4, code S).
- Dec 2, 2025: Grant or award of MNPR derivative securities (Form 4, code A).
- Jul 14, 2025: Option exercise of MNPR shares (Form 4, code X).
Other insiders filing for Monopar Therapeutics (MNPR)
- Robinson Chandler, Chief Executive Officer
- Cittadine Andrew, Chief Operating Officer
- Vu Quan Anh, Chief Financial Officer
- Tsuchimoto Kim R, Director
- Anderson Raymond, Director
- RIOUX PATRICE, Officer